Literature DB >> 28677771

MicroRNA profiling of platelets from immune thrombocytopenia and target gene prediction.

Gang Deng1, Shifang Yu2, Yunlei He3, Tao Sun2, Wei Liang3, Lu Yu3, Deyi Xu3, Qiang Li4, Ri Zhang1.   

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count and insufficient platelet production. Previous studies identified that microRNAs (miRNAs/miRs) are important for platelet function. However, the regulatory role of miRNAs in the pathogenesis of thrombocytopenia in ITP remains unclear. The aim of the present study is to isolate differentially expressed miRNAs, and identify their roles in platelets from ITP. A total of 5 ml blood from 22 patients with ITP and 8 healthy controls was isolated for platelet collection. A microarray assay was performed to analyze the differentially expressed miRNAs in the patients with ITP and healthy patients. Furthermore, the expression of differentially expressed miRNAs was verified by reverse transcription‑quantitative polymerase chain reaction. In addition, the target mRNAs of the differentially expressed miRNAs were predicted via miRWalk databases, and the target genes and miRNAs were classified by Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes analyses. In the present study, 115 miRNAs were identified to be differentially expressed in platelets from patients with ITP compared with the healthy controls (>3‑fold alteration; P<0.05). Among them, 57 miRNAs were upregulated in ITP, while 58 miRNAs were downregulated. Bioinformatic prediction demonstrated that hsa‑miR‑548a‑5p, hsa‑miR‑1185‑2‑3p, hsa‑miR‑30a‑3p, hsa‑miR‑6867‑5p, hsa‑miR‑765 and hsa‑miR‑3125 were associated with platelet apoptosis and adhesion in ITP. The present study performed miRNA profiling of platelets from patients with ITP and the results may aid in the understanding of the regulatory mechanism of ITP.

Entities:  

Mesh:

Year:  2017        PMID: 28677771     DOI: 10.3892/mmr.2017.6901

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Identification of potential key molecules and signaling pathways for psoriasis based on weighted gene co-expression network analysis.

Authors:  Xin Shu; Xiao-Xia Chen; Xin-Dan Kang; Min Ran; You-Lin Wang; Zhen-Kai Zhao; Cheng-Xin Li
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

Review 2.  The Extensive Regulation of MicroRNA in Immune Thrombocytopenia.

Authors:  Yuerong Zhao; Siyuan Cui; Yan Wang; Ruirong Xu
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

Review 3.  MicroRNAs in Autoimmunity and Hematological Malignancies.

Authors:  Mirco Di Marco; Alice Ramassone; Sara Pagotto; Eleni Anastasiadou; Angelo Veronese; Rosa Visone
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

4.  Elucidation of the Mechanisms and Molecular Targets of Yiqi Shexue Formula for Treatment of Primary Immune Thrombocytopenia Based on Network Pharmacology.

Authors:  Yunyao Jiang; Nan Liu; Shirong Zhu; Xiaomei Hu; Dennis Chang; Jianxun Liu
Journal:  Front Pharmacol       Date:  2019-10-01       Impact factor: 5.810

Review 5.  MicroRNAs as a Potential Quality Measurement Tool of Platelet Concentrate Stored in Blood Banks-A Review.

Authors:  Jersey Heitor da Silva Maués; Caroline de Fátima Aquino Moreira-Nunes; Rommel Mário Rodriguez Burbano
Journal:  Cells       Date:  2019-10-15       Impact factor: 6.600

Review 6.  Platelets in ITP: Victims in Charge of Their Own Fate?

Authors:  Vivianne S Nelson; Anne-Tess C Jolink; Sufia N Amini; Jaap Jan Zwaginga; Tanja Netelenbos; John W Semple; Leendert Porcelijn; Masja de Haas; Martin R Schipperus; Rick Kapur
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

7.  Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation.

Authors:  Ming Jing Wang; Yan Sun; Ying Song; Ju Ning Ma; Zi Qing Wang; Xiao Qing Ding; Hai Yan Chen; Xue Bin Zhang; Min Min Song; Xiao Mei Hu
Journal:  Front Med (Lausanne)       Date:  2022-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.